Mereo BioPharma Group plc filings document a U.K. clinical-stage biopharmaceutical issuer whose Nasdaq-listed ADSs represent ordinary shares. Recent Form 8-K reports furnish quarterly and annual financial results, rare-disease pipeline updates, conference presentation materials, cash runway disclosures, and clinical-program announcements for setrusumab, alvelestat, and related partnered assets.
The filing record also covers proxy governance, executive compensation and equity-award disclosures, board composition matters, ADS and ordinary-share listing information, and Nasdaq continued-listing compliance notices. These documents frame Mereo's capital structure, governance practices, material events, and development-stage public-company reporting.
Mereo BioPharma Group plc reported first quarter 2026 results and updates on its rare disease pipeline. For the quarter ended March 31, 2026, net loss narrowed to $6.7 million from $12.9 million a year earlier, helped by lower general and administrative expenses of $4.0 million versus $7.3 million. Research and development spending rose to $4.7 million from $3.9 million, mainly from higher setrusumab costs.
Cash and cash equivalents were $36.2 million as of March 31, 2026, compared with $41.0 million at December 31, 2025, and the company reiterates that this is expected to fund operations into mid-2027. Setrusumab’s two Phase 3 studies in osteogenesis imperfecta did not reach their primary fracture endpoints but showed strong improvements in bone mineral density, vertebral fractures and patient-reported outcomes, with a safety profile consistent with prior studies. Mereo and partner Ultragenyx have begun discussions with regulators on a potential pediatric path.
Mereo is seeking a partner to run a single Phase 3 alvelestat trial in approximately 220 AATD-LD patients over 18 months and expects vantictumab partner āshibio to start a Phase 2 trial in ADO2 in the second half of 2026.
Mereo BioPharma Group plc has called its 2026 annual general meeting for May 14, 2026 in London. Shareholders are asked to adopt the U.K. statutory annual report and accounts for 2025, re-appoint PricewaterhouseCoopers LLP as auditor and approve the auditors’ 2026 remuneration.
Advisory votes will cover the U.K. directors’ remuneration report, an updated three‑year directors’ remuneration policy, and 2025 compensation for named executive officers. Shareholders will also vote on the re‑election of Justin Roberts, Dr. Daniel Shames and Marc Yoskowitz to the board.
The board seeks authority to allot shares or grant rights over shares up to a maximum aggregate nominal amount of £3,591,354.73 and to disapply statutory pre‑emption rights on the same nominal amount, both running until June 30, 2029. The company reports 798,078,829 ordinary shares issued and outstanding as of April 7, 2026.
Mereo BioPharma Group plc is convening its 2026 Annual General Meeting on May 14, 2026 to ask shareholders to approve eleven resolutions, including authority to allot shares and disapply pre-emption rights up to a maximum nominal amount of £3,591,354.73 expiring on June 30, 2029.
The meeting materials include the Company’s U.K. statutory annual report and accounts for the year ended December 31, 2025, re-appointment of PwC as auditor, approval of remuneration-related proposals, re-election of three directors, and references a Form S-3 shelf registration effective May 22, 2024 permitting ADS offerings up to $175 million. Shares outstanding were 798,078,829 as of April 7, 2026.
Mereo BioPharma Group plc reported that Dr. Annalisa Jenkins has informed the company she will not stand for re-election to its Board of Directors at the 2026 annual general meeting of shareholders scheduled for May 14, 2026.
She will continue to serve as a director until her current term expires immediately prior to that meeting. The company stated that Dr. Jenkins’ decision is not due to any disagreement with the company or the board regarding operations, policies, or practices, indicating a planned transition rather than a dispute-driven departure.
Mereo BioPharma Group plc files its annual report describing a rare‑disease focused biopharma business built around late‑stage assets setrusumab for osteogenesis imperfecta and alvelestat for severe alpha‑1 antitrypsin deficiency‑associated lung disease.
The company reports that two Phase 3 pediatric and young adult studies of setrusumab (Orbit and Cosmic) did not achieve statistical significance on their primary fracture‑reduction endpoints, although both met secondary endpoints with strong improvements in bone mineral density versus comparators and maintained a consistent safety profile. Further analyses are underway to determine next regulatory steps.
Alvelestat has shown positive Phase 2 biomarker and symptom data in AATD‑LD and is being advanced toward a single global Phase 3 trial, with alignment from U.S. and European regulators on primary endpoints. Mereo also highlights multiple partnering deals (Ultragenyx, āshibio, ReproNovo, Feng Biosciences) and ongoing royalty‑ and milestone‑based economics, while emphasizing risks around funding needs, clinical trial execution, intellectual property, and continued Nasdaq listing. As of June 30, 2025, non‑affiliate equity market value was approximately $368,470,120, and 798,078,829 ordinary shares were outstanding as of March 18, 2026.
Mereo BioPharma reported a 2025 net loss of $41.9M, slightly improved from $43.3M in 2024, on $0.5M of revenue. Research and development expenses fell to $17.8M and general and administrative costs to $23.0M, reflecting lower spending on alvelestat, etigilimab and corporate functions.
Cash and cash equivalents were $41.0M as of December 31, 2025, down from $69.8M a year earlier, which the company expects to fund operations into mid‑2027. Shareholders’ equity stood at $40.9M.
In its pipeline, the Phase 3 Orbit and Cosmic studies of osteoporosis drug setrusumab in osteogenesis imperfecta did not meet primary fracture endpoints but showed strong bone mineral density gains, vertebral fracture reductions and positive patient‑reported outcomes, with further analyses ongoing. For alvelestat, Mereo has aligned with regulators on a single ~220‑patient Phase 3 trial in AATD‑lung disease and designed a potential Phase 2b bronchiectasis study to support partnering. The company also outlicensed vantictumab for osteopetrosis to āshibio, which plans a Phase 2 study in the second half of 2026.
Jacquet Pierre reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Pierre Jacquet reported equity awards rather than open‑market trades. He received share options for 66,000 shares at a price of $0.00 per share and 106,848 deferred restricted stock units, both recorded as direct beneficial ownership.
The options vest in substantially equal monthly installments over one year from the February 26, 2026 grant date. The deferred restricted stock units are granted in lieu of annual cash compensation, vest monthly over the following plan year, and are generally settled in American Depositary Shares about 180 days after separation of service. Each ADS represents five ordinary shares.
Mereo BioPharma Group plc director Marc J. Yoskowitz reported equity compensation awards. He received share options covering 66,000 shares at an exercise price of $0.0000 per share, classified as a grant or award acquisition.
He was also granted 96,163 deferred restricted stock units, which are provided in the form of American Depositary Shares instead of annual cash compensation. The options vest in substantially equal monthly installments over one year from the February 26, 2026 grant date, while the deferred restricted stock units vest in substantially equal monthly installments over the plan year and are generally settled in ADSs 180 days after separation of service.
Shames Daniel reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Daniel Shames reported receiving new equity awards. On February 26, 2026, he was granted 66,000 share options and 96,163 deferred restricted stock units as compensation. The options vest in substantially equal monthly installments over one year from the grant date.
The deferred restricted stock units are granted in the form of American Depositary Shares instead of annual cash compensation for non-executive directors and also vest in substantially equal monthly installments over the plan year. Each ADS represents five ordinary shares of Mereo BioPharma Group plc.